Chem-/Biotech

Innovative, allogeneic cell therapies for the regeneration of damaged cartilage tissue

BIONCaRT GmbH

BIONCaRT GmbH is a life science company that is working on a phase I/IIa clinical trial for the market approval of a human stem cell therapeutic for the treatment of focal cartilage damage to the knee joint. The stem cells extracted from the umbilical cord tissue are embedded in a collagen-containing carrier matrix. In a minimally invasive procedure, a surgeon inserts the cell-laden matrix into the damaged cartilage. The cell therapy stimulates the formation of new cartilage tissue and relieves pain and inflammation. The company’s vision is to address other joints and other indications such as osteoarthritis with innovative cell therapies in the future, thereby significantly improving the quality of life of many people.

TGFS has held a stake in the company since 2024. Other investors include bm|t and private investors.